Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

02 déc. 2025 09h00 HE | Source: BetaGlue Therapeutics SpA

BetaGlue Therapeutics Expands its Clinical Trial in Italy after obtaining from the Italian Ministry of Health Approval to conduct its clinical study in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)

MILAN, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a pioneering Italian clinical-stage oncology company developing an innovative radiotherapy solution for...
12 nov. 2025 12h00 HE | Source: BetaGlue Therapeutics SpA

MHRA Approves BetaGlue Therapeutics’ Clinical Trial Application for YntraDose™ in unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)

MHRA Approves BetaGlue Therapeutics’ Clinical Trial Application for YntraDose™ in unresectable Locally Advanced Pancreatic Cancer (uLPDAC)
18 oct. 2025 05h15 HE | Source: ITM Isotope Technologies Munich SE

ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025

Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus across patient subgroups Berlin, Germany, October 18, 2025 – ITM Isotope Technologies Munich...
13 oct. 2025 05h00 HE | Source: ITM Isotope Technologies Munich SE

ITM Appoints Annette Breunig as Chief People Officer

Global HR leader to drive ITM’s long-term human resources strategy, support organizational development and corporate growth Garching / Munich, Germany, October 13, 2025 – ITM Isotope Technologies...
01 oct. 2025 05h00 HE | Source: NUCLIDIUM AG

NUCLIDIUM Receives Notice of Allowance for Composition-of-Matter Patent Covering FAP inhibitor-based Radiodiagnostics and Therapeutics in the United States

Basel, Switzerland / Munich, Germany, October 01, 2025 – NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced that it...
24 sept. 2025 05h00 HE | Source: ITM Isotope Technologies Munich SE

ITM and TerThera Sign Supply Agreement for Medical Radioisotope Terbium-161

Garching / Munich, Germany, and Breda, the Netherlands, September 24, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and TerThera BV, a leading...
22 sept. 2025 03h50 HE | Source: BetaGlue Therapeutics SpA

BetaGlue Therapeutics Announces the Appointment of Alexis Peyroles as New Chief Executive Officer

BetaGlue Therapeutics Announces the Appointment of Alexis Peyroles as New Chief Executive Officer
16 sept. 2025 05h07 HE | Source: ITM Isotope Technologies Munich SE

ITM to Present COMPETE Dosimetry Data and Host Satellite Symposium at EANM 2025

Garching / Munich, Germany, September 16, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will unveil dosimetry data from its...
16 sept. 2025 05h00 HE | Source: NUCLIDIUM AG

NUCLIDIUM to Present Clinical Data from Phase I/II Study for Copper-based PET-Diagnostic in Neuroendocrine Tumors at EANM 2025

Basel, Switzerland / Munich, Germany, September 16, 2025 – NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced that...
08 sept. 2025 11h05 HE | Source: Research and Markets

Brachytherapy Market Trends and Industry Outlook 2025-2030 - AI-Driven Dosimetric Modeling Offers Adaptive Treatment Plans, Projecting Optimal Outcomes Based on Historical Data

Dublin, Sept. 08, 2025 (GLOBE NEWSWIRE) -- The "Brachytherapy Market Forecast 2025-2030" has been added to ResearchAndMarkets.com's offering. The Brachytherapy Market is set for significant...

Page suivante